Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy.
BACKGROUND
The transplantation of encapsulated cells genetically engineered to secrete human erythropoietin (hEpo) represents an alternative to repeated injections of the recombinant hormone for the treatment of Epo-responsive anemia. In the present study, the ability of primary human foreskin fibroblasts to secrete high levels of hEpo and the importance of cis-acting elements and infection conditions on transgene expression level were assessed.


METHODS
The transduction efficiency was first evaluated with beta-galactosidase (LacZ)-encoding retroviral vectors derived from the murine leukemia retrovirus (MLV) pseudotyped either with an amphotropic envelope or with the G glycoprotein of vesicular stomatitis virus (VSV-G). Human fibroblasts were then infected with an amphotropic hEpo-expressing retroviral vector, which was modified by insertion of a post-transcriptional regulatory element from the woodchuck hepatitis virus (WPRE) and a Kozak consensus sequence (KZ). Human Epo production was further optimized by increasing the multiplicity of infection and by selecting high producer cells. The survival and the transgene expression of these fibroblasts were finally evaluated in vivo. The cells were encapsulated into microporous hollow fibers and subcutaneously implanted in nude mice.


RESULTS
A secretion level of approximately 5 IU hEpo/10(6) cells/day was obtained with the basal vector. A 7.5-fold increase in transgene expression was observed with the insertion of WPRE and KZ elements. Finally, according to the optimization of infection conditions, we obtained a 40-fold increase in hEpo secretion, reaching approximately 200 IU hEpo/10(6) cells/day. The in vivo experiments showed an increase in the hematocrit during the first 2 weeks and elevated levels exceeding 60% were maintained over a 6-week period.


CONCLUSIONS
These results indicate that primary human fibroblasts represent a promising source for encapsulated cell therapy.
Schwenter
F
F
Division of Surgical Research & Gene Therapy Center, CHUV, Lausanne University Medical School, 1011 Lausanne, Switzerland.
Déglon
N
N
Aebischer
P
P
D000818:Animals; D004921:Erythropoietin / Q000235:genetics* / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism / Q000637:transplantation; D018014:Gene Transfer Techniques; D005809:Genes, Regulator; D017930:Genes, Reporter; D005822:Genetic Vectors; D006801:Humans; D009052:Leukemia Virus, Murine; D051379:Mice; D008819:Mice, Nude; D014161:Transduction, Genetic
D004921:Erythropoietin